Gynecologic Oncology

Nemvaleukin monotherapy and with pembrolizumab for ovarian cancer

June 18, 2021

Nemvaleukin alfa (Alkermes) was mostly well tolerated and indicated antitumor activity as both monotherapy and in combination with pembrolizumab among patients with advanced solid tumors, according to study results presented at the annual meeting of the American Society of Clinical Oncology (ASCO), held virtually from June 4-8.

Subcutaneous nemvaleukin dosing for advanced ovarian cancer

June 11, 2021

“I believe in combinatorial immunotherapeutic regimens in an attempt to increase efficacy and durability of response,” said principal investigator Omid Hamid, MD, director of clinical research and immunotherapy at The Angeles Clinic and Research Institute in Los Angeles, an affiliate of Cedars-Sinai Medical Center.